Toll-like receptors in multiple sclerosis

Current Topics in Microbiology and Immunology

Volumn 336, Issue 1, 2009, Pages 155-168

  Racke, Michael K ^a   Drew, Paul D ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECOGNITION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; DEMYELINATION; ENVIRONMENTAL FACTOR; HOST RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY;

ANIMALIA;

ANIMALS; AUTOIMMUNITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; TOLL-LIKE RECEPTORS;

EID: 77951634046     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-00549-7_9     Document Type: Review

References (91)

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH (1992) Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 31:333-336
2. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE (1989) Encephalitogenic T cells in the B10. PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 124:132-143
3. Arnason BG (1983) Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol Clin 1:765-782
4. Bailey SL, Schreiner B, McMahon EJ, Miller SD (2007) CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4 + T(H)-17 cells in relapsing EAE. Nat Immunol 8:172-180
5. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR (2005) The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA 102:10976-10980
6. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T(H)17 cells. Nature 453:1051-1057
7. Brennan CA, Anderson KV (2004) Drosophila: the genetics of innate immune recognition and response. Annu Rev Immunol 22:457-483
8. Brown AM, McFarlin DE (1981) Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest 45:278-284
9. Bsibsi M, Persoon-Deen C, Verwer RW, Meeuwsen S, Ravid R, Van Noort JM (2006) Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 53:688-695
10. Bsibsi M, Ravid R, Gveric D, van Noort JM (2002) Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 61:1013-1021
11. Cao Z, Henzel WJ, Gao X (1996a) IRAK: a kinase associated with the interleukin-1 receptor. Science 271:1128-1131
12. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV (1996b) TRAF6 is a signal transducer for interleukin-1. Nature 383:443-446
13. Compston A (2004) The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg 106:246-248
14. Compston DA, Vakarelis BN, Paul E, McDonald WI, Batchelor JR, Mims CA (1986) Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 109(Pt 2): 325-344
15. Deng C, Radu C, Diab A, Tsen MF, Hussain R, Cowdery JS, Racke MK, Thomas JA (2003) IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity. J Immunol 170:2833-2842
16. Du C, Yao SY, Ljunggren-Rose A, Sriram S (2002) Chlamydia pneumoniae infection of the central nervous system worsens experimental allergic encephalitis. J Exp Med 196:1639-1644
17. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T (2003a) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4:491-496
18. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, Golenbock DT (2003b) LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198:1043-1055
19. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK (2005) Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 62:1345-1356
20. Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 354:942-955
21. Gay D, Dick G, Upton G (1986) Multiple sclerosis associated with sinusitis: case-controlled study in general practice. Lancet 1:815-819
22. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM (1993) Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72:551-560
23. Guo B, Chang EY, Cheng G (2008) The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 118:1680-1690
24. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Hacker G, Mann M, Karin M (2006) Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439:204-207
25. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H (2000) Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 192:595-600
26. Hansen BS, Hussain RZ, Lovett-Racke AE, Thomas JA, Racke MK (2006) Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol 172:94-103
27. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688
28. Hausmann S, Wucherpfennig KW (1997) Activation of autoreactive T cells by peptides from human pathogens. Curr Opin Immunol 9:831-838
29. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Tolllike receptor 5. Nature 410:1099-1103
30. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200
31. Herrmann I, Kellert M, Schmidt H, Mildner A, Hanisch UK, Bruck W, Prinz M, Nau R (2006) Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Infect Immun 74:4841-4848
32. Horwitz MS, Sarvetnick N (1999) Viruses, host responses, and autoimmunity. Immunol Rev 169:241-253
33. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
34. Johnson AJ, Suidan GL, McDole J, Pirko I (2007) The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology? Int Rev Neurobiol 79:73-97
35. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276
36. Kabelitz D (2007) Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19:39-45
37. Katz-Levy Y, Neville KL, Girvin AM, Vanderlugt CL, Pope JG, Tan LJ, Miller SD (1999) Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J Clin Invest 104:599-610
38. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S (1999) Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11:115-122
39. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K, Akira S (2001) Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 167:5887-5894
40. Kennedy MK, Torrance DS, Picha KS, Mohler KM (1992) Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149:2496-2505
41. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, Zanardo RC, Bonder C, James WG, Robbins SM, Kubes P (2004) TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol 173:7070-7077
42. Khoruts A, Miller SD, Jenkins MK (1995) Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol 155:5011-5017
43. Kurtzke JF (1993) Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6:382-427
44. Lampropoulou V, Hoehlig K, Roch T, Neves P, Calderon Gomez E, Sweenie CH, Hao Y, Freitas AA, Steinhoff U, Anderton SM, Fillatreau S (2008) TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 180:4763-4773
45. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, Rosenberg PA, Volpe JJ, Vartanian T (2002) The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 22:2478-2486
46. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T (2003) Activation of innate immunity in the CNS triggers neurodegeneration through a Tolllike receptor 4-dependent pathway. Proc Natl Acad Sci USA 100:8514-8519
47. Lenz DC, Lu L, Conant SB, Wolf NA, Gerard HC, Whittum-Hudson JA, Hudson AP, Swanborg RH (2001) A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol 167:1803-1808
48. Li S, Strelow A, Fontana EJ, Wesche H (2002) IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 99:5567-5572
49. Lublin FD (1982) Delayed, relapsing experimental allergic encephalomyelitis in mice. Role of adjuvants and pertussis vaccine. J Neurol Sci 57:105-110
50. Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10:153-187
51. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913-919
52. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11:335-339
53. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA, Jr. (1998) MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2:253-258
54. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo A, Bernini ML, Gambi D, Prencipe M (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153-159
55. Miller SD, Karpus WJ (1994) The immunopathogenesis and regulation of T-cell-mediated demy-elinating diseases. Immunol Today 15:356-361
56. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, Katz-Levy Y, Carrizosa A, Kim BS (1997) Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 3:1133-1136
57. Mosmann TR, Coffman RL (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173
58. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A (1998) The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 187:2097-2101
59. Nair A, Frederick TJ, Miller SD (2008) Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 65:2702-2720
60. Nikbin B, Bonab MM, Khosravi F, Talebian F (2007) Role of B cells in pathogenesis of multiple sclerosis. Int Rev Neurobiol 79:13-42
61. Noseworthy JH (1999) Progress in determining the causes and treatment of multiple sclerosis. Nature 399:A40-A47
62. Oldstone MB (1987) Molecular mimicry and autoimmune disease. Cell 50:819-820
63. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T (2003) TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 4:161-167
64. Panitch HS (1994) Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36(Suppl):S25-S28
65. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, Piesche M, Schroers R, Weiss E, Kirschning CJ, Rochford CD, Bruck W, Becher B (2006) Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 116:456-464
66. Racke MK (2001) Experimental autoimmune encephalomyelitis (EAE). Curr Protoc Neurosci Chap 9:Unit 9.7
67. Racke MK, Hu W, Lovett-Racke AE (2005) PTX cruiser: driving autoimmunity via TLR4. Trends Immunol 26:289-291
68. Rapp NS, Gilroy J, Lerner AM (1995) Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 74:415-418
69. Rocken M, Racke M, Shevach EM (1996) IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today 17:225-231
70. Rowe DC, McGettrick AF, Latz E, Monks BG, Gay NJ, Yamamoto M, Akira S, O'Neill LA, Fitzgerald KA, Golenbock DT (2006) The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci USA 103:6299-6304
71. Sadovnick AD, Ebers GC (1993) Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 20:17-29
72. Sanders P, De Keyser J (2007) Janus faces of microglia in multiple sclerosis. Brain Res Rev 54:274-285
73. Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R (2000) Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 10:1139-1142
74. Segal BM, Chang JT, Shevach EM (2000) CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 164:5683-5688
75. Sibley WA, Bamford CR, Clark K (1985) Clinical viral infections and multiple sclerosis. Lancet 1:1313-1315
76. Sriram S, Mitchell W, Stratton C (1998) Multiple sclerosis associated with Chlamydia pneumo-niae infection of the CNS. Neurology 50:571-572
77. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17:1-14
78. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21:335-376
79. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF, Akira S (2000) Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2-and MyD88-dependent signaling pathway. J Immunol 164:554-557
80. Tauber SC, Nau R, Gerber J (2007) Systemic infections in multiple sclerosis and experimental autoimmune encephalomyelitis. Arch Physiol Biochem 113:124-130
81. Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B (2006) Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 177:7505-7509
82. Vanderlugt CL, Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2:85-95
83. Visser L, Jan de Heer H, Boven LA, van Riel D, van Meurs M, Melief MJ, Zahringer U, van Strijp J, Lambrecht BN, Nieuwenhuis EE, Laman JD (2005) Proinflammatory bacterial peptidogly-can as a cofactor for the development of central nervous system autoimmune disease. J Immunol 174:808-816
84. Visser L, Melief MJ, van Riel D, van Meurs M, Sick EA, Inamura S, Bajramovic JJ, Amor S, Hintzen RQ, Boven LA, t'Hart BA, Laman JD (2006) Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am J Pathol 169:1671-1685
85. Waldner H, Collins M, Kuchroo VK (2004) Activation of antigen-presenting cells by micro-bial products breaks self tolerance and induces autoimmune disease. J Clin Invest 113:990-997
86. Wolf NA, Amouzegar TK, Swanborg RH (2007) Synergistic interaction between Toll-like receptor agonists is required for induction of experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 185:115-122
87. Xu J, Drew PD (2007) Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 178:1904-1913
88. Xu J, Racke MK, Drew PD (2007) Peroxisome proliferator-activated receptor-alpha agonist feno-fibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem 103:1801-1810
89. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301:640-643
90. Yamin TT, Miller DK (1997) The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation. J Biol Chem 272:21540-21547
91. Zekki H, Feinstein DL, Rivest S (2002) The clinical course of experimental autoimmune encepha-lomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol 12:308-319.